Experienced in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency

Drago Bratkovic

72 King William Rd, 
North Adelaide, SA, AU 
Experienced in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
72 King William Rd, 
North Adelaide, SA, AU 
OverviewLocationsClinical Research

Overview

Drago Bratkovic practices in North Adelaide, Australia. Mr. Bratkovic is rated as an Experienced expert by MediFind in the treatment of Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency. His top areas of expertise are Pompe Disease, Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Adrenoleukodystrophy (ALD), and Mucopolysaccharidoses (MPS).

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency.

Gender
Male

Locations

72 King William Rd, North Adelaide, SA 5006, Australia
Other Locations
Frome Rd, Adelaide, SA 5000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
View 1 Less Clinical Trial

46 Total Publications

Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003).
Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003).
Journal: Neurology
Published: February 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bratkovic's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile